Advanced Techniques in Protein Measurement
” We have utilized innovative strategies that permit us to determine thousands of proteins at the same time in a small amount of sample. We conducted this in 428 individuals to identify biomarkers that can indicate whether a client with motor disruptions or cognitive difficulties has damage to the dopamine system in the brain. We discovered that if a client has a disorder in the dopamine system, the levels of the biomarker DDC increase, despite where they are in the course of the illness. A crucial discovery is that this biomarker can be measured in blood, where it is considerably increased, especially in Parkinsons disease,” says Oskar Hansson, a professor of neurology at Lund University and a specialist at Skåne University Hospital.
Verification and Implications for Diagnosis
They demonstrated that the brand-new biomarker is also considerably increased in blood by evaluating blood plasma samples from 174 people. Damage to the dopamine system in the brain can likewise be detected through PET cam evaluations.
” Since the symptoms of numerous neurodegenerative brain diseases look like each other, there is a significant danger of misdiagnosis and therefore improper treatment. Therefore, it is vital to discover much safer diagnostic tools and approaches, and we are concentrating on that in our research. I believe that in the future, different brain diseases will be dealt with even before the signs end up being evident, and blood markers will be vital in determining the best individuals in a easy and affordable way.”
Reference: “DOPA decarboxylase is an emerging biomarker for Parkinsonian disorders including preclinical Lewy body disease” by Joana B. Pereira, Atul Kumar, Sara Hall, Sebastian Palmqvist, Erik Stomrud, Divya Bali, Piero Parchi, Niklas Mattsson-Carlgren, Shorena Janelidze and Oskar Hansson, 18 September 2023, Nature Aging.DOI: 10.1038/ s43587-023-00478-y.
We discovered that if a client has a disorder in the dopamine system, the levels of the biomarker DDC boost, regardless of where they are in the course of the illness. A crucial discovery is that this biomarker can be measured in blood, where it is substantially increased, especially in Parkinsons illness,” says Oskar Hansson, a teacher of neurology at Lund University and a consultant at Skåne University Hospital.
” Since the symptoms of various neurodegenerative brain diseases resemble each other, there is a significant risk of misdiagnosis and hence inappropriate treatment. I believe that in the future, different brain diseases will be treated even before the signs end up being obvious, and blood markers will be important in recognizing the right people in a cost-efficient and basic manner.”
Lund University scientists have found a biomarker, DOPA decarboxylase (DCC), that may assist identify Parkinsons disease and similar disorders by showing dopamine system damage in the brain. This finding provides expect simpler and earlier detection and treatment of neurodegenerative diseases.
Scientists at Lund University have actually discovered a blood marker that can determine Parkinsonian illness. Their findings were recently published in the journal Nature Aging.
The marker in concern is called DOPA decarboxylase (DCC). In the present study, DCC was discovered to be raised in individuals with Parkinsons illness as well as in people with other diseases that result in dopamine shortage in the brain.
However, the marker was regular in other brain illness such as Alzheimers disease. The scientists even observed that DCC rose in individuals with Parkinsons lots of years before they developed any signs.